marrow with ineffective hematopoiesis, and a propensity to progress to acute myeloid leukemia (AML) 1 . The complexity and heterogeneity of MDS, insufficient description of disrupted genetic networks, and lack of mouse models has stymied our understanding and treatment of this disease. Recent seminal findings provide insight into a subtype of MDS called 5q-syndrome, which is associated with an isolated deletion of chromosome arm 5q. 5q-syndrome originates in a hematopoietic stem cell and is defined by an isolated heterozygous deletion of chromosome arm 5q, macrocytic anemia, variable neutropenia, and abnormal megakaryocytes associated with elevated platelets 2 . Exploration of candidate protein-coding genes within the minimally deleted region on chromosome 5q
revealed a critical role of RPS14 in erythroid apoptosis and macrocytic anemia in mice [3] [4] [5] ( Figure 1 ). Our group investigated the contribution of small non-coding RNAs, referred to as microRNAs (miRNAs), to the pathogenesis of 5q-syndrome 6 . We have recently cell intrinsic mechanism, increased megakarycytes and platelets result in part because of paracrine expression of interleukin-6 (IL-6). Elevated IL-6 expression was observed in TRAF6-activated cells, and marrow of patients with deletion of chromosome 5q showed increased levels of IL-6 mRNA. Macrocytic anemia was not observed following loss of miR-145 and miR-146a, suggesting that distinct mechanisms regulate erythroid and megakaryocytic defects in 5q-syndrome. In support of this hypothesis, it is reported that coordinate loss of miR-145 and RPS14 cooperate to alter both erythroid and megakaryocytic production similar to patients with 5q-syndrome 5 . In these mice, erythroid hypoplasia was due to loss of RPS14, while loss of miR-145 increased megakaryopoiesis in transgenic mice 5 . In this latter study, megakaryocyte production was The former two genes are within the minimally deleted region, while miR-146a is telomeric to this region but deleted in approximately 75% of patients. Loss of RPS14 in hematopoietic cells is associated with erythroid defects and macrocytic anemia. Loss of miR-145 is associated with derepression of FLI1 and TIRAP. Loss of miR-146a is associated with derepression of TRAF6. Coordinated activation of TIRAP and TRAF6 (two genes of the innate immune pathway) mediate increased survival of hematopoietic cells resulting in clonal dominance, while expression of IL-6 results in paracrinemediated stimulation of megakaryopoiesis and platelet production. FLI1 also contributes to enhanced megakaryopoiesis and platelet production. IL-6 is known to increase transcription of FLI1 mRNA levels in hematopoietic cells, thus further augmenting FLI1 expression.
